The effects of spironolactone on nephron function in patients with diabetic nephropathy

Renal Failure

Volumn 30, Issue 10, 2008, Pages 982-991

  Ustundag, Ayten ^a   Tugrul, Armagan ^a   Ustundag, Sedat ^a   Sut, Necdet ^a   Demirkan, Bora ^a  

^a TRAKYA UNIVERSITY   (Turkey)

Author keywords

Aldosterone; Angiotensin II; Diabetic nephropathy; Spironolactone

Indexed keywords

CILAZAPRIL; CREATININE; POTASSIUM; PROTEIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIABETIC NEPHROPATHY; DIABETIC PATIENT; DRUG EFFECT; DRUG TOLERABILITY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY FUNCTION; MALE; MICROALBUMINURIA; NEPHRON; NON INSULIN DEPENDENT DIABETES MELLITUS; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; AGED; ALBUMINURIA; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETIC NEPHROPATHIES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; SPIRONOLACTONE;

EID: 57049133582     PISSN: 0886022X     EISSN: 15256049     Source Type: Journal    
DOI: 10.1080/08860220802389342     Document Type: Article

References (38)

1. Locatelli F, Pozzoni P, Del Vecchio L. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol. 2004;15(1):S25-S29.
2. S. Anderson. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int. 1997;63:107-110.
3. Strippoli GF, Bonifati C, Craig M, Navaneethan SD, Craig JC. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease. Cochrane Database Syst Rev. 2006;18:CD006257.
4. Staessen J, Lijnen P, Fagard F, Amery A. Rise in plasma concentration of aldosterone during long-term angiotensin II suppression. J Endocrinol. 1981;91:457-465.
5. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. J Int Med Res. 2001;29:13-21.
6. Sato A, Hayashi K, Naruse M, Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension. 2003;41:64-68.
7. Epstein M. Aldosterone as a determinant of cardiovascular and renal dysfunction. J R Soc Med. 2001;94:378-383.
8. Schiffrin EL, Franks DJ, Gutkowska J. Effect of aldosterone on vascular angiotensin II receptors in the rat. Can J Physiol Pharmacol. 1995;63:1522-1527.
9. Barr CS, Lang CC, Hanson J, Arnott M, Kennedy N, Struthers AD. Effects of adding spironolactone to an angiotensin-converting enzyme inhibitor in chronic congestive heart failure secondary to coronary artery disease. Am J Cardiol. 1995;76:1259-1265.
10. Bauersachs J, Heck M, Fraccarollo D, et al. Addition of spironolactone to angiotensin-converting enzyme inhibition in heart failure improves endothelial vasomotor dysfunction: Role of vascular superoxide anion formation and endothelial nitric oxide synthase expression. J Am Coll Cardiol. 2002;39:351-358.
11. Brown NJ, Nakamura S, Ma L, et al. Aldosterone modulates plasminogen activator inhibitor-1 and glomerulosclerosis in vivo. J Am Coll Cardiol. 2002;16:351-358.
12. Sun Y, Zhang JQ, Ramires FJA. Local angiotensin II and transforming growth factor-β ± 1 in renal fibrosis in rats. Hypertension. 2000;35:1078-1084.
13. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2006;29(Suppl. 1):S43-S48.
14. Bakker AJ. Detection of microalbuminuria. Receiver operating curve analysis favors albumin-to-creatinine ratio over albumin concentration. Diabetes Care. 1999;22:307-313.
15. Schmidt BMW, Sammer U, Fleischmann I, Schlaich M, Delles C, Schmieder RE. Rapid non genomic effects of aldosterone on the renal vasculature in humans. Hypertension. 2006;47:650-655.
16. Arima S, Kohagura K, Xu HL, et al. Non-genomic vascular action of aldosterone in the glomerular microcirculation. J Am SocNephrol. 2003;14:2255-2263.
17. Bianchi S, Bigazzi R, Campese VM. Long term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease. Kidney Int. 2006; 70: 2116-2123.
18. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting enzyme inhibition on diabetic nephropathy. N Engl J Med. 1993;329:1456-1462.
19. van den Meiracker AH, Baggen RGA, Pauli S, et al. Spironolactone in type 2 diabetic nephropathy: Effects on proteinuria, blood pressure and renal function. J Hypertens. 2006;24:2285-2292.
20. Chrysostomou A, Pedagogos E, MacGregor L, Becker GJ. Double-blind, placebo controlled study on the effects of the aldosterone receptor antagonist spironolactone in patients who have persistent proteinuria and are on long-term angiotensin-converting enzyme inhibitor therapy, with or without an angiotensin II receptor blocker. Clin J Am Soc Nephrol. 2006;1:256-262.
21. Rachmani R, Slavachevsky I, Amit M, Levi Z, Kedar Y, Berla M. The effect of spironolactone, cilazapril and their combination on albuminuria in patients with hypertension and diabetic nephropathy is independent of blood pressure reduction: A randomized controlled study. Diabet Med. 2004;21:471-475.
22. Rossing K, Schjoedt KJ, Smidt UM, Boomsma F, Parving H-H. Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy. Diabetes Care. 2005;28:2106-2112.
23. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone in diabetic nephropathy. Kidney Int. 2005;68:2829-2836.
24. Schjoedt KJ, Rossing K, Juhl TR, et al. Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int. 2006;70:536-542.
25. Watisaka M, Spiro MJ, Spiro RG. Synthesis of type IV collagen by cultured glomerular cells and comparison of its regulation by glucose and other factors with that of type IV collagen. Diabetes. 1995;43:95-103.
26. Buter H, Navis G, Dullaart RPF, de Zeeuw D, Jong PE. Time course of the antiproteinuric and renal haemodynamic responses to losartan in microalbuminuric IDDM. Nephrol Dial Transplant. 2001;16:771-775.
27. de Zeeuw D, Remuzzi G, Parving H-H, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: Lessons from RENAAL. Kidney Int. 2004;65:2309-2320.
28. Rossing P, Hommel E, Smidt UM, Parving H-H. Reduction in albuminuria predicts a beneficial effect on diminishing the progression of human diabetic nephropathy during antihypertensive treatment. Diabetologia. 1994;37:511-516.
29. Pitt B, Zannad F, Remme WJ, et al. The Randomized Aldactone Evaluation Study. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709-717.
30. Schjoedt KJ, Andersen S, Rossing P, Tarnow L, Parving H-H. Aldosterone escape during angiotensin II receptor blockade in diabetic nephropathy is associated with enhanced decline in GFR. Diabetologia. 2004;47:1936-1939.
31. Naruse M, Tanabe A, Sato A, et al. Aldosterone breakthrough during angiotensin II receptor antagonist therapy in stroke-prone spontaneously hypertensive rats. Hypertension. 2002;40:28-33.
32. Giacchetti G, Sechi LA, Rilli S, Carey RM. The reninangiotensin- aldosterone system, glucose metabolism and diabetes. Trends Endocrinol Metab. 2005;16:120-126.
33. Campion J, Maestro B, Molero S, Davila N, Carranza MC, Calle C. Aldosterone impairs insulin responsiveness in U-937 human promonocytic cells via the downregulation of its own receptor. Cell Biochem Funct. 2002;20:237-245.
34. Giacchetti G, Faloia E, Mariniello B, et al. Overexpresion of the renin-angiotensin system in human visceral adipose tissue in normal and overweight subjects. Am J Hypertens. 2002;15:381-388.
35. Shimamoto K, Shiiki M, Ise T, et al. Does insulin resistance participate in an impaired glucose tolerance in primary aldosteronism. J Hum Hypertens. 1994;10:755-759.
36. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60:820-825.
37. U.S. Renal Data System. USRDS 2003 Annual Data Report: Atlas of End Stage Renal Disease in the United States. Bethesda, Md.: National Institute of Health, National Institute of Diabetes and Digestive and Kidney Diseases; 2003:1-72.
38. Henderson L, Harris S, Brown E, Gruen R, Victor C. Clinical outcomes, quality of life, and costs in the North Thames Dialysis Study of elderly people on dialysis: A perspective cohort study. Lancet. 2002;356:1543-1550.